No augmentation of indoleamine 2,3 ‐dioxygenase (ido) activity through belatacept treatment in liver transplant recipients

Conclusion: These data provide evidence that belatacept is not associated with detectable IDO induction in the clinical transplant setting compared to tacrolimus‐treated patients. This article is protected by copyright. All rights reserved.

Source: Clinical and Experimental Immunology - December 22, 2017 Category: Allergy & Immunology Authors: Sinda Bigenzahn, Birgit Juergens, Benedikt Mahr, Johann Pratschke, Alfred Koenigsrainer, Thomas Becker, Dietmar Fuchs, Gerald Brandacher, Alexander Kainz, Ferdinand Muehlbacher, Thomas Wekerle Tags: Original Article Source Type: research